Last reviewed · How we verify
M6229
At a glance
| Generic name | M6229 |
|---|---|
| Sponsor | A.P.J. Vlaar |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229 (PHASE1)
- Intravenously Administered M6229 in Critically Ill Sepsis Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M6229 CI brief — competitive landscape report
- M6229 updates RSS · CI watch RSS
- A.P.J. Vlaar portfolio CI